Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer : a cost-utility analysis
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
 
ID 789197
Author(s) Joerger, M; Matter-Walstra, K; Früh, M; Kühnel, U; Szucs, T; Pestalozzi, B; Schwenkglenks, M
Author(s) at UniBasel Matter-Walstra, Klazien
Year 2011
Title Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer : a cost-utility analysis
Journal Annals of oncology
Volume 22
Number 3
Pages / Article-Number 567-74
Keywords cetuximab, chemoimmunotherapy, cost-effectiveness, non-small-cell lung cancer, qualy
Abstract

Adding cetuximab to standard chemotherapy results in a moderate increase of overall survival in patients with advanced non-small-cell lung cancer (NSCLC), but the cost-effectiveness is unknown. Materials and methods: A Markov model was constructed based on the results of the First-Line ErbituX in lung cancer randomized trial, adding cetuximab to cisplatin-vinorelbine first-line chemotherapy in patients with advanced NSCLC. The primary outcome was the incremental cost-effectiveness ratio (ICER) of adding cetuximab, expressed as cost per quality-adjusted life year (QALY) gained, and relative to a willingness-to-pay threshold of ?60?000/QALY. The impact of cetuximab intermittent dosing schedules on the ICER was also evaluated.; Adding cetuximab to standard chemotherapy leads to a gain of 0.07 QALYs per patient at an additional cost of ?26?088. The ICER for adding cetuximab to chemotherapy was ?376?205 per QALY gained. Intermittent cetuximab dosing schedules resulted in ICERs per QALY gained between ?31?300 and ?83?100, under the assumption of equal efficacy.; From a health economic perspective, the addition of cetuximab to standard first-line chemotherapy in patients with epidermal growth factor receptor-expressing advanced NSCLC cannot be recommended to date, due to a high ICER compared with other health care interventions. Treatment schedules resulting in more favorable cost-utility ratios should be evaluated.

Publisher Oxford University Press
ISSN/ISBN 0923-7534
edoc-URL http://edoc.unibas.ch/dok/A5844560
Full Text on edoc No
Digital Object Identifier DOI 10.1093/annonc/mdq431
PubMed ID http://www.ncbi.nlm.nih.gov/pubmed/20843984
ISI-Number WOS:000287750700010
Document type (ISI) Article
 
   

MCSS v5.8 PRO. 0.479 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |    
08/08/2020